Related by context. All words. (Click for frequent words.) 83 Patient Enrollment 83 Meets Primary Endpoint 82 Completes Patient Enrollment 81 Phase 2b Clinical Trial 81 First Patient Treated 80 Completes Enrollment 80 Phase IIb Clinical Trial 79 Study Evaluating 79 Phase III Trial 78 Phase 1b Clinical Trial 78 Phase 2b Trial 78 Initiates Clinical Trial 78 Initiates Enrollment 78 Topline Results 78 Gout Drug 78 Pivotal Trial 77 Initiates Phase II 77 Phase 2a Trial 77 Lupus Drug 77 Submits NDA 77 Receives Orphan Drug Designation 77 Phase IIb Trial 77 Oral Fingolimod 77 Preclinical Data 77 Phase III Clinical Trial 77 Successfully Completes Phase 77 First Patient Dosed 77 Clinical Trial Results 77 Combination REOLYSIN R 77 Clinical Trial Evaluating 77 Pivotal Phase III 77 Phase 2a Clinical Trial 76 Oral Calcitonin 76 NDA Submission 76 IND Filing 76 Patient Accrual 76 Granted Orphan Drug 76 Improves Survival 76 Study Showed 76 Dose Ranging 76 Epilepsy Drug 76 Initiates Phase III 76 Patients Enrolled 76 Lung Cancer Drug 76 Demonstrates Positive 76 Initiate Phase III 76 Files IND 76 Advanced Melanoma 76 Initiates Clinical 76 Telik Announces 76 Pivotal Phase 75 Mylan Receives Approval 75 Clinical Trial Data 75 Phase Ib Clinical Trial 75 Pivotal Study 75 Migraine Drug 75 Drug Candidate 75 Schizophrenia Drug 75 Immunomedics Announces 75 Presents Positive 75 Earns Milestone Payment 75 Demonstrates Significant 75 Prolongs Survival 75 Receives Orphan Drug 75 Phase III Pivotal 74 Initiate Phase 74 Prostate Cancer Vaccine 74 Diamyd Medical Diamyd 74 Confirmatory Phase 74 Novel Oral 74 Trial Evaluating 74 Dose Escalation 74 Antitumor Activity 74 Rheumatoid Arthritis Drug 74 Pooled Analysis 74 Investigational Compound 74 HCV Protease Inhibitor 74 Achieves Primary Endpoint 74 Study Demonstrates 74 Double Blind Placebo 74 Sangamo BioSciences Announces 74 Receives Fast Track 74 FDA Approvals 74 Expanded Indication 74 JAK2 Inhibitor 74 pralatrexate injection folate analogue 74 FDA Accepts 74 Begins Dosing 74 Employment Inducement Awards 74 Drug Fails 74 NOVAVAX 74 Treatment Naïve 74 Teva Provides Update 74 Pivotal Clinical Trial 74 Severe Sepsis 74 Demonstrates Sustained 74 Cholesterol Lowering Drug 74 Milestone Payment 74 Less Invasive 74 Plaque Psoriasis 74 Taro Receives 74 Vaccine Adjuvant 74 Single Dose 73 Tezampanel 73 II Clinical Trial 73 Biomarker Study 73 Investigational Drug 73 Collaborators Present 73 Recurrent Breast Cancer 73 Osteoporosis Drug 73 Second Pivotal Phase 73 GeoMet Announces 73 Randomized Clinical Trials 73 Arthritis Drug 73 Cholesterol Drug 73 Adjuvant Treatment 73 Lung Cancer Trial 73 Resistant Hypertension 73 NMT Medical Announces 73 Pulmonary Arterial Hypertension 73 FDA APPROVES 73 Patient Enrolment 73 Anti Tumor Activity 73 Schizophrenia Treatment 73 5q MDS 73 Announce Initiation 73 TRANSDUR ™ 73 Receives Approvable Letter 73 Nasdaq Delisting Notice 73 Anti Tumor 73 Present Preclinical Data 73 Preclinical Study 73 Schweitzer Mauduit Announces 73 Shows Promising 73 Revises FY# Outlook 73 Dose Ranging Study 73 Improves Outcomes 73 Relapsed Multiple Myeloma 73 LMI Aerospace Announces 73 PPD Declares 73 Receives Milestone Payment 73 Long Term Efficacy 73 Poniard Pharmaceuticals Announces 73 Inhaled Insulin 73 Clinical Study Shows 73 Neoadjuvant Chemotherapy 73 Anti Clotting Drug 73 Hormone Refractory Prostate Cancer 73 Rheumatoid Arthritis Patients 73 R lenalidomide 73 Therapeutic Competitors Companies 73 Hepatitis C Treatment 73 Nasdaq Deficiency Notice 73 Phase 2b Study 73 Previously Treated 72 TO AVOID PREGNANCY WHILE 72 Prostate Cancer Patients 72 FDA Okays 72 Combination Treatment 72 Refractory Angina 72 Revises FY# Guidance 72 Blood Pressure Drug 72 Adjunctive Therapy 72 Aeolus Pharmaceuticals Announces 72 Alvine Pharmaceuticals 72 novel orally inhaled 72 Oral Laquinimod 72 XPEL Announces 72 Novel Antibiotic 72 Phase III Trials 72 Platelet Inhibition 72 Enrolls First 72 Patients Treated With 72 Kaydon Corporation Announces 72 Investigational Treatment 72 Subgroup Analysis 72 Psoriasis Drug 72 Nanophase Announces 72 Spectrum Pharmaceuticals Announces 72 Commences Phase 72 Completes Dosing 72 Treatment Experienced 72 PDUFA Date 72 Presents Preclinical Data 72 Initiates Dosing 72 By JENNIFER LEARN 72 TRANSDUR ® 72 Annual Meeting Date 72 Receives CE Marking 72 Sapacitabine 72 Investigational Agent 72 Hematological Malignancies 72 Statin Drugs 72 Acute Heart Failure 72 TriCo Bancshares Announces 72 Renal Cell Carcinoma 72 Key Milestones 72 Metastatic Melanoma 72 Randomized Clinical Trial 72 Initiates Phase 2b 72 Backs FY# Outlook 72 ST Elevation Myocardial 72 Demonstrates Efficacy 72 Randomized Trials 72 Treated Patients 72 Projected Release Date 72 Randomized Double blind 72 Treatment Naive Patients 72 Nuvelo Announces 72 Antibody Drug Conjugate 72 Efficacy Results 72 Vertex Pharmaceuticals Announces 72 Heart Failure Patients 72 Submits Biologics License Application 72 Drug Prevents 72 Statistically Significant 71 Relapsing Multiple Sclerosis 71 Crofelemer budesonide foam 71 Randomized Double Blind 71 Brentuximab Vedotin SGN 71 Hsp# Inhibitor 71 EntreMed Presents 71 Presents Preclinical 71 Demonstrates Potent 71 Announces Tentative Approval 71 Nicotine Vaccine 71 Allos Therapeutics Announces 71 Announce License Agreement 71 Balloon Angioplasty 71 Therapeutic Competitors companiesandmarkets.com adEgemonye 71 Announces FDA Clearance 71 Anticancer Activity 71 Inhaled Nitric Oxide 71 Drug Coated Stent 71 Completes Patient Enrolment 71 Telik logo TELINTRA 71 Newly Diagnosed Patients 71 Abstract Accepted 71 Pharmacyclics Announces 71 Lung Cancer Survival 71 Testosterone Patch 71 Drug Shows Promise 71 Neurocrine Biosciences Announces 71 GATTEX TM 71 Survival Benefit 71 Sagent Pharmaceuticals Announces 71 Shows Efficacy 71 STERIS Corporation Announces 71 Insteel Industries Announces 71 Patient Dosing 71 Treat Heart Failure 71 Flamel Technologies Announces 71 Patients Suffering 71 Elderly Patients 71 Mg Usa 71 Lifts FY# Outlook 71 COVIDIEN 71 Testosterone Gel 71 Fungal Infections 71 RNAi Therapeutics 71 AVI BioPharma Announces 71 Demonstrated Significant 71 FOLOTYN ® 71 Hematological Cancers 71 Shows Promise Against 71 TriMas Corporation Announces 71 Autologous Stem Cell Transplantation 71 Metastatic Prostate Cancer 71 Non Invasive Treatment 71 Generic Version 71 Adjuvant Chemotherapy 71 Improve Survival 71 PDL BioPharma Announces 71 Cervical Dysplasia 71 Treatment Reduces 71 IN PATIENTS WITH 71 Showed Significant 71 Is Well Tolerated 71 Demonstrate Significant 71 Versus Placebo 71 R MSCRAMM 71 Kidney Transplant Patients 71 ALN HPN 71 Receive Milestone Payment 71 Node Positive 71 PRN FDA Approves 71 Metabolic Disorder 71 Announcement acc 71 Announces Initiation 71 Lupus Nephritis 70 Information Portal StockProfile.com 70 Slow Progression 70 INSPIRE Trial Phase III 70 Glufosfamide 70 Ebola Vaccine 70 Univest Corporation Declares 70 Telaprevir VX 70 Regeneron Pharma 70 Announce Merger Agreement 70 Aflibercept 70 Preclinical Models 70 Q3 Profit Decreases 70 dependent kinase inhibitor 70 Patient Outcomes 70 Appears Safe 70 Drug Coated Stents 70 Osteoporosis Drugs 70 Myeloma Patients 70 Initiates Clinical Trials 70 Intracranial Aneurysms 70 Initiate Clinical Trial 70 Cites Positive 70 vapreotide acetate 70 Fourth Quarter Cash Dividend 70 Balance Sheet Restructuring 70 Randomized Phase 70 Drug Combo 70 Significantly Improved 70 Pharmacokinetic Study 70 Combo Therapy 70 Clinical Outcome 70 Announce Collaboration Agreement 70 Castration Resistant Prostate Cancer 70 Launches Generic Version 70 Profitable Third Quarter 70 Vicriviroc 70 Study Shows Promise 70 Pivotal Phase II 70 Successfully Treated 70 Breast Cancer Recurrence 70 Million Milestone Payment 70 Rotavirus Vaccine 70 Chronic Hepatitis C 70 JAK Inhibitor 70 Minimally Invasive Treatment 70 Effectively Treats 70 Underwritten Public 70 BOVESPA PFRM3 70 Carotid Stenting 70 Knee Osteoarthritis 70 Study Evaluates 70 CFO Resignation 70 Upcoming Deadline 70 Boosts Survival 70 Aztreonam Lysine 70 Medicure Announces 70 Renal Cancer 70 Submits Response 70 Milestone Payment From 70 Systemic Delivery 70 SABER ™ 70 Initiates Phase 70 EastGroup Properties Announces 70 Statin Therapy 70 Hematology Molecular Pathology 70 WorldHeart Announces 70 Vasogen Announces 70 OxyContin Maker 70 Romiplostim 70 See CLINICAL PHARMACOLOGY 70 FDA Clears 70 Clinical Study 70 Artery Disease 70 Weight Loss Drug 70 Vicor Technologies Announces 70 Improved Survival 70 Sustained Reduction 70 Winmark Corporation Announces 70 Patients Treated 70 Cardiac Resynchronization 70 Licenses Novel 70 Significant Reduction 70 Files Investigational 70 Reports Preclinical Data 70 Crowflight Announces 70 Bone Metastases 70 CYP#A# CYP#D# 70 Proc Am Soc 70 Backs FY# View 70 Develop Novel 70 Phase IIa Clinical Trial 70 Osteoarthritis Patients 70 Successfully Treats 70 Reaffirms FY# Outlook 70 Glatiramer Acetate 70 Advanced Colorectal Cancer 70 Asthma Treatment 70 Levels Linked 70 ELADUR ™ 70 Prospective Randomized 70 Randomized Phase III 70 Novel Compounds 70 Announces Poster Presentations 70 Newly Diagnosed Multiple Myeloma 70 Nasdaq Notice Regarding 70 Fewer Side Effects 70 Merge Healthcare Announces 70 Unfractionated Heparin 70 Anworth Announces 70 Phase III Clinical Trials 69 ΞΕΝΗ ΔΗΜΟΣΙΕΥΣΗ ΑΝΑΚΟΙΝΩΣΗInfosys Finacle 69 Geokinetics Announces 69 Hormone Receptor Positive 69 Sleep Disturbances 69 NPS Pharmaceuticals Announces 69 Randomized Phase II 69 Well Tolerated 69 Novel Antibody 69 Controlled Study 69 Private Equity Financing 69 VIVITROL ® 69 MEK Inhibitor 69 Data Suggest 69 Advanced Renal Cell 69 Clinical Trial Enrollment 69 Backs FY# Guidance 69 Proves Effective 69 FDA Approves Novel 69 Xcytrin R 69 Inhaled Corticosteroids 69 Significantly Improves 69 Lowers Risk 69 carcinoma mCRC 69 Submits Application 69 Bone Fracture 69 Tyrosine Kinase Inhibitor 69 Elagolix 69 Treatment Shows Promise 69 Proxy Proposals 69 Anti Inflammatory Drug 69 Genes Predict 69 MITTEILUNG UEBERMITTELT VON BUSINESS 69 recurrent metastatic ovarian cancer 69 Regains NASDAQ 69 Inflammatory Disease 69 Pivotal Trials 69 Pafuramidine 69 pan histone deacetylase 69 Ridaforolimus 69 Hypertensive Patients 69 Hernia Repair 69 THERAPEUTICS 69 Gene Variant 69 Jumps Higher 69 Milestone Payments 69 Venous Thromboembolism 69 Gene Linked 69 Nasdaq Delisting Notification 69 CEPHALON 69 Patients Undergoing 69 Gets FDA Clearance 69 Anticancer Drug 69 Anemia Drug 69 Measurement Specialties Announces 69 Gastric Cancer 69 Recommends Approval 69 Inflammatory Markers 69 Proven Effective 69 Purported Class 69 Improve Patient Outcomes 69 IBERIABANK Corporation Reports 69 PHASE III 69 IND Application 69 SHAREHOLDERS ARE STRONGLY ADVISED 69 Upcoming Conferences 69 J.P. Morgan Healthcare 69 COMPLETES ACQUISITION OF 69 Fast Track Status 69 Syncria R 69 AFFYMETRIX 69 Vitrasert R 69 Complete Remission 69 Regenerative Cells 69 Medoro Resources Announces 69 Clinical Evaluation 69 FDA Approves Drug 69 Gene Variants 69 Long Term Survival 69 Reduces Risk 69 Novel Inhibitor 69 Stock Repurchase Authorization 69 NASDAQ Delisting Notice 69 Predict Risk 69 Advanced Ovarian Cancer 69 TO EDUCATE 69 Corcept Therapeutics Announces 69 SulphCo Announces 69 Habersham Bancorp Announces 69 Vaccine Protects Against 69 FY# EPS View 69 Randomized Controlled Trials 69 Diabetic Foot Ulcer 69 Stereotaxis Announces 69 By JAMAAL ABDUL 69 Desvenlafaxine Succinate 69 An Opportunity Awaits 69 Enzo Biochem Reports 69 DOR BioPharma Announces 69 Virco Announces 69 Protease Inhibitor 69 Oral Mucositis 69 Golimumab 69 Hedgehog Pathway 69 Ischemic Stroke 69 WE WILL CONTINUE TO 69 Patients Receiving 69 Receives NASDAQ 69 Novel Therapeutic 69 Heartburn Drugs 69 Personalized Immunotherapy 69 Oral Formulation 69 Controlled Trial 69 Plus Ribavirin 69 Transplant Patients 69 PET FROM 69 dasatinib Sprycel ® 69 NexMed Receives 69 includes TOLAMBA TM 69 ACTEMRA TM 69 Virus Linked 69 Sono Tek Announces 69 Gentium Announces 69 Randomized Study 69 Newmont Declares Regular 69 XTend Medical XMDC 69 Stent Coating 69 BioElectronics Announces 69 platform HDL Mimetic 69 HDAC Inhibitor 69 ANADIGICS Announces 69 Cypher Sirolimus 69 Acute Myocardial Infarction 69 ADVANCE ILLUMINATE 69 RNAi Therapeutic 69 AAG geldanamycin analog 69 MOCON Announces 69 Reveals Positive 69 Cutaneous T 69 AUDIO PROVIDED BY 69 Restructures Debt 69 WHO TOOK 69 Overactive Bladder 68 Muscle Function 68 IDEXX Laboratories Announces 68 Oral Cladribine 68 Antipsychotic Drug 68 Confirms Efficacy 68 Custirsen 68 Colorectal Cancer Patients 68 Atypical Hemolytic Uremic Syndrome 68 M.D. Ph.D. 68 Generic Versions 68 Third Quarter Dividend 68 Recurrent Glioblastoma 68 Patient Treated 68 Two Upcoming Investor 68 Liver Toxicity 68 Eluting Stent 68 Unanimously Recommends Approval 68 pentadentate logo R 68 Acute Ischemic Stroke 68 Initiate Phase II 68 Upcoming Investor 68 Safinamide 68 Unsolicited Proposal From 68 Otelixizumab 68 Complicated Skin 68 Bosutinib 68 Rigel R# 68 HuCAL PLATINUM ® CysDisplay 68 Reaffirms FY# Guidance 68 Heart Transplant Recipients 68 Multiple Myeloma Patients 68 Announces Presentation 68 Identifies Potential 68 Shown Effective 68 RESPONSIBILITY OF 68 CCX# B 68 EXECUTIVE SUMMARY II 68 KELLEHER @ newsday.com 68 Treatment Resistant 68 ERBITUX cetuximab 68 Stem Cell Treatment 68 MKC# MKC# PP 68 Treat Anemia 68 Flexsteel Announces 68 Prostate Cancer Treatment 68 PremierWest Bancorp Announces 68 MIND CTI LTD 68 YOUR LOCAL ANIMAL SHELTER 68 Prognostic Significance 68 acute peptic ulcer 68 Guidelines Recommend 68 INDUSTRY ASSESSMENTS 68 Q2 Profit Decreases 68 Osteoporosis Treatment 68 Aggressive Prostate Cancer 68 Cell Transplants 68 Provides Shareholder 68 Zicam Extreme 68 REG1 Anticoagulation System 68 Biomerix Corporation 68 Therapeutic Potential 68 TB Vaccine 68 BioSante Pharmaceuticals Announces 68 REPORTS THIRD QUARTER 68 Spinal Fractures 68 CYPHER R Sirolimus Eluting 68 THAT ARE DIFFICULT TO 68 Obese Patients 68 Pirfenidone 68 OTC BB PVCT 68 myocardial infarction ventricular fibrillation 68 Receives Favorable 68 signal detection CTSD 68 Localized Prostate Cancer 68 Acne Drug 68 Tumor Growth 68 Increased Mortality 68 Positive Opinion 68 REPORTS RECORD 68 Guides FY# FY# 68 PLEASE READ THE FOLLOWING 68 VIVUS Announces 68 ST Segment Elevation 68 Cardiovascular Outcomes 68 Drug Eluting Coronary Stent 68 Phase III Pivotal Trial 68 Perifosine KRX 68 Guidelines Issued 68 Experimental Vaccine 68 Antiviral Activity 68 www.syntapharma.com 68 ACADIA Pharmaceuticals 68 Issued Patent 68 Aethlon Medical Announces 68 SHORT ON CHEDDAR 68 Stock Buyback Plan 68 Onyx Pharmaceuticals Announces 68 Ovitrelle R Serostim 68 Previously Disclosed 68 Ocrelizumab 68 Improve Diagnosis 68 Left Ventricular Hypertrophy 68 Evaluate Strategic Alternatives 68 Toromont Announces 68 Oceaneering Announces 68 Fondaparinux 68 Cancer Recurrence 68 Astralis Ltd. 68 Hythiam Announces 68 Polymerase Inhibitor 68 Disease Progression 68 DRUG DISCOVERY 68 Clostridium difficile Infection 68 CORPORATION ANNOUNCES 68 Eur J 68 Receives Complete Response 68 Blood Thinner 68 Sunesis Pharma 68 PAUL Minn.MN 68 CYT# potent vascular disrupting 68 FEMALES SHOULD BE ADVISED 68 Strengthens Balance Sheet 68 Relapsing Remitting Multiple Sclerosis 68 Humanized Anti 68 Schiavo Autopsy 68 Serious Infections 68 Miraculins Announces 68 Novel Compound 68 Gene Variation 68 Randomized Double Blind Placebo 68 Demonstrates Potential 68 Results Release Date 68 Clot Busting 68 Diabetic Macular Edema 68 Naive Patients 68 CONMED Corporation 68 BCG refractory carcinoma 68 Resubmission 68 Stent Placement 68 Bush Embraces Pause 68 Slows Progression 68 COLLABORATION WITH 68 acetonide FA 68 Diabetic Kidney Disease 68 Vaccine Candidate 68 Threshold Pharmaceuticals Announces 68 COMUNICADO DE 68 Backs FY# Forecast 68 topical antifungal product 68 Tuberculosis Vaccine 68 Therapeutic Antibody 68 Wizzard Software Announces 68 Seasonal Influenza Vaccine 68 NASDAQ Listing Requirements 68 Acute Exacerbations 68 Bipolar Depression 68 Helps Predict 68 REPORTS FIRST QUARTER 68 Improve Patient Safety 68 Blood Pressure Drugs 68 SIDE EFFECTS CHEAP ONLINE 68 BY DAVE VAN 68 MICRODUR TM 68 Transcept Pharmaceuticals 68 Bladex Announces 68 Arthritis Drugs 68 Refractory Hodgkin Lymphoma 68 undergoing elective percutaneous 68 Namenda Memantine HCl 68 Aggressive Reduction 68 Obese Teens 68 SNOW WILL DEVELOP 68 Chronic Hepatitis B 68 PRAECIS PHARMACEUTICALS INCORPORATED 68 ATRA IV 68 Prostate Tumors 68 IS ASSOCIATED WITH 68 Bone Marrow Cells 68 Initiated Phase 68 evaluating mipomersen 68 AND FOURTH QUARTER 68 Shingles Vaccine 68 Q2 Loss Narrows 68 Reduced Risk 68 Dose Finding 68 Mg Uk 68 Metastatic Colorectal Cancer 68 Transdermal Patch 68 PROMUS R 68 Test Detects 68 NEWS RELEASE THE COMPANY 68 Blast Applications BLAP 68 Underscores Importance 68 HUMIDITIES WILL 68 Board Authorizes 68 Awarded Patents 68 Sinks Lower 68 VentiRx Pharmaceuticals 68 AND ECONOMIC 68 SPRYCEL ® 68 Rapid Expansion 68 AREAS AFFECTED 68 Therapeutic Competitors 68 R Bortezomib 68 Demonstrates Ability 68 NASA Expendable Launch 68 Monotherapy 68 ODT metoclopramide HCl PEPCID 68 Aliskiren 68 KB Home Swings 68 Antiplatelet Therapy 68 Senetek PLC Announces 68 Chemotherapy Regimen 68 CINDY KIBBE NEW HAMPSHIRE 68 Anti Nausea 68 BioElectronics Corporation Announces 68 RISKS AND UNCERTAINTIES INHERENT 68 investigational pharmacologically unique 68 Presents Positive Preclinical 68 Ovarian Cancer Treatment 68 Diabetic Neuropathic Pain 68 Commercialize Novel 68 Quarterly Dividend Payment 68 Anemia Drugs 68 J Am Coll 68 Infected Patients 68 Vascular Grafts 68 Record Second Quarter 68 Flagstone Re Announces 68 Clinical Efficacy 68 Anti CD# Antibody 68 KEMET Announces 68 Renal Function 68 Reiterates FY# Outlook 68 Britney Spears Conservatorship 68 Glaucoma Treatment 68 Anticancer Agent 68 www.vivus.com 68 Treating Chronic 68 Multicenter Phase 68 Valhi Reports 68 Brain Metastases 67 Male Contraceptive 67 Nymox Reports 67 Diabetic Patients 67 Limb Ischemia 67 Taglich Brothers Initiates Coverage 67 Rotavirus Vaccines 67 Valve Replacement 67 Therapy Reduces 67 Explore Strategic Alternatives 67 HER2 Positive Breast Cancer 67 Sitebrand Announces 67 BRE Properties Announces 67 Capsules CII 67 Metastatic Renal Cell Carcinoma 67 Prognostic Value 67 Synta Announces 67 Synalloy Corporation Announces 67 Study Reinforces 67 Q3 Loss Widens 67 Xeloda ® 67 Peginterferon 67 Clin Oncol 67 Important Milestone 67 Painkiller Abuse 67 microRNA Therapeutics 67 Blood Clot Risk 67 Premenopausal Women 67 Hedgehog Pathway Inhibitor 67 HemaCare Reports 67 AirIQ Announces 67 Novel Mechanism 67 Dynasil Announces 67 Therapy Improves 67 BUT THEIR 67 BIOLASE Announces 67 Eszopiclone 67 Provides Update Regarding 67 Preclinical Efficacy 67 PATENT FOR 67 PRINCE CASPIAN REVIEW 67 CROSSTEX ENERGY 67 Inc. www.micromet inc.com 67 Shows Promise 67 Multiple Ascending Dose 67 Transplant Patient 67 ScottsMiracle Gro Announces 67 Adjuvant Therapy 67 Pfizer Discontinues 67 GOLAR LNG 67 monoclonal antibody IgG1 Mab 67 Study Casts Doubt 67 Synthetic Peptide 67 Audited Financials 67 PHRM 67 Preterm Labor 67 FUSILEV ® 67 atypical Hemolytic Uremic Syndrome 67 FDA Panel Recommends 67 BY JIM MOORE 67 Antiplatelet 67 Sustained Efficacy 67 Q1 Loss Narrows 67 Study Shows Benefits 67 Significantly Reduces 67 AvalonBay Communities Announces 67 PLEASE REFER TO 67 modified glutathione analog 67 Pending Acquisition 67 Methylnaltrexone 67 Embolic Protection 67 familial amyloidotic polyneuropathy FAP 67 Study Validates 67 Uterine Fibroid Embolization 67 Record Third Quarter 67 RockTenn Announces 67 Eighth Consecutive 67 Diabetic Nephropathy 67 Laryngeal Cancer 67 Breast Cancer Treatment 67 Crit Rev 67 Enlarged Prostate 67 CysDisplay R 67 ViRexx Announces 67 rasagiline tablets 67 LOUISMO 67 Pediatric Patients 67 ISSI Announces 67 Headwaters Incorporated Announces 67 MarketAxess Announces 67 BY PAUL HUGHES 67 THIS RECALL 67 WGNB Corp. Announces 67 NYSE Amex Listing 67 ANN INTERN MED 67 NASDAQ Deficiency Notice 67 XTENT Announces 67 Aortic Dissection 67 BY SUE KIESEWETTER 67 Remission Maintenance 67 HONORED WITH 67 Hematopoietic Stem Cell Transplantation 67 Cosimo Cutri 67 MANNKIND 67 First BanCorp Announces 67 Pre Cancerous 67 REMINDER ORLive Presents 67 AND DEVELOPMENT OF 67 Erratic Session 67 Avise PG SM 67 delivers fluocinolone acetonide FA 67 Strengthen Balance Sheet 67 FY# Guidance 67 Mouse Model 67 Cinacalcet 67 Gene Therapy Trial 67 LifeVantage Announces 67 Previously Untreated 67 Avian Flu Vaccine 67 Minimally Invasive Procedure 67 Cognitive Deficits 67 Significantly Reduced 67 Lowers FY# Outlook 67 Significant Milestones 67 Enrolling Patients 67 J Shoulder Elbow 67 Shows Statistically Significant 67 PetroQuest Energy Announces 67 Cognitive Impairment 67 ThermoDox ® clinical 67 Universal Flu Vaccine 67 Secondary Hyperparathyroidism 67 FIRST QUARTER FINANCIAL RESULTS 67 Kinase Inhibitor 67 virus HCV protease inhibitor 67 TELINTRA R 67 Insulin Pen 67 Myelodysplastic Syndromes 67 Epeius Biotechnologies Corporation 67 Endovascular Treatment 67 Intravenous Formulation 67 Erectile Dysfunction Drug 67 Total Knee Arthroplasty 67 Acute Attacks 67 Clinical Trials Update 67 oncolytic virus therapies 67 Secures Financing 67 Lowering Blood Pressure 67 Phase III PREGNANT PROCHIEVE 67 Abiraterone Acetate 67 Novel Treatments 67 Skin Lesions 67 Primary Hypercholesterolemia 67 QHR Announces 67 INCLUDING ONE 67 Genetic Mutation 67 Postmenopausal Women 67 TM Drug Eluting 67 Disease Modifying 67 Factor Xa Inhibitor 67 Patent Covering 67 BY MARK SCHMETZER 67 Contract Signings 67 ThermoGenesis Announces 67 Biopharmaceutical Industry 67 Webcast Alert Isis Pharmaceuticals 67 Bare Metal Stents 67 Seasonal Allergic Rhinitis 67 ORLive Presents 67 Stem Cell Procedure 67 Orthop Surg 67 Potent Antiviral Activity 67 Million Convertible Debt 67 Treating Depression 67 Commence Phase 67 Antipsychotic Drugs 67 DOCUMENTS BECAUSE THEY CONTAIN 67 Cervical Cancer Vaccine 67 Amend Merger Agreement 67 Study Shows Significant 67 Q4 Profit Decreases 67 Advanced Prostate Cancer 67 events thrombocytopenia neutropenia 67 evaluating picoplatin 67 Generic Protonix 67 personalized cellular immunotherapy 67 Antigen Specific 67 PANVAC VF 67 Mercury Fillings 67 AMERISAFE Announces 67 Often Misdiagnosed 67 COVER YOUR BODY 67 Announces Definitive Agreements 67 Enteral Feed Devices 67 Prostate Cancer Survival 67 evaluating tivozanib 67 Microwave Ablation System 67 Orckit Communications Reports 67 Accelr8 Announces 67 BY RYAN ERNST 67 pharmacogenomic translational research 67 Pegloticase 67 Ranolazine 67 Beta Blocker 67 BY MATTHEW O'ROURKE 67 Eculizumab 67 Metabolic Efficiency 67 Late Breaker 67 PRN EpiCept 67 Kidney Failure 67 RIP CURRENTS ARE 67 brass@knews.com 67 tranquilizers diazepam 67 Jennifer Convertibles Reports 67 Antiviral Drugs 67 Q3 Loss Narrows